Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

evobrutinib

- PMLiVE

Merck KGaA and Pfizer collaborate on lupus

Companies team up with academics to research treatments for autoimmune disorder

- PMLiVE

Doctors criticise FDA over Lemtrada rejection

Say Sanofi/Genzyme’s MS drug should have been approved

- PMLiVE

Merck KGaA loses global head of R&D

Senior reshuffle also sees departure of head of Merck Millipore

- PMLiVE

Genzyme MS campaign to raise awareness of swimming benefits

Will work with the Multiple Sclerosis Association of America

Biogen Idec building

NICE turns down Biogen Idec’s oral MS drug

UK HTA body says Tecfidera is not a cost-effective use of NHS resources

- PMLiVE

Merck KGaA appoints biosimilar head

Simon Sturge joins from Boehringer Ingelheim

- PMLiVE

Merck appoints new legal and auditing heads

Friederike Rotsch and Barbara Weiland take on senior roles

Biogen Idec building

EC approves Biogen’s oral MS drug Tecfidera

Will compete with Novartis' Gilenya and Sanofi's Aubagio

- PMLiVE

Merck KGaA loses CFO to Lanxess

Matthias Zachert joins chemical company as CEO

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

- PMLiVE

Merck Serono appoints chief medical officer

Steven Hildemann joins from Merck & Co

- PMLiVE

Royalty Pharma buys bigger Tecfidera interest

Agrees $510m deal with Biogen Idec for IP share of multiple sclerosis drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links